Alondra Elizabeth Cardenas Gonzalez, MD
Family Practice · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gonzalez’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A163608 · Current
Licensed to practise in California · since 2019 · expires 2027-07-31 · University of Illinois College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Medicaid work
$288,391 in 2024
Medicaid paid $288,391 for 6,819 billed services this clinician did in 2024, up to 129 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 656 | $263,997 |
| Short return visit (20+ min) | 1,005 | $13,318 |
| Short return visit | 409 | $3,334 |
| Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 181 | $2,853 |
| Return visit (30+ min) | 136 | $2,483 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 445 | $1,062 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 18 | $583 |
| Long return visit (40+ min) | 20 | $387 |
| Screening for depression is documented as negative, a follow-up plan is not required | 110 | $334 |
| OFF/OP EST MAY X REQ PHY/QHP | 15 | $35 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 431 | $4 |
| Pain severity quantified; pain present (COA) (ONC) | 19 | $0 |
| 2024 | 6,819 | 24 | 129 | $288,391 |
| 2023 | 5,197 | 18 | 84 | $306,257 |
| 2022 | 2,637 | 17 | 67 | $184,588 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 815 | $298,830 |
| Short return visit (20+ min) | 806 | $3,192 |
| Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 79 | $1,376 |
| Short return visit | 442 | $1,208 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 666 | $453 |
| Return visit (30+ min) | 65 | $375 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | 88 | $345 |
| Long return visit (40+ min) | 24 | $172 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 124 | $153 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 22 | $82 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose | 20 | $40 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 23 | $27 |
2022
| Clinic visit/encounter, all-inclusive | 489 | $180,651 |
| Short return visit (20+ min) | 366 | $1,775 |
| Return visit (30+ min) | 148 | $943 |
| Long return visit (40+ min) | 42 | $349 |
| Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use | 35 | $338 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 336 | $268 |
| Screening for depression is documented as negative, a follow-up plan is not required | 42 | $114 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | 15 | $54 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 78 | $45 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 145 | $27 |
| Alcohol and/or drug screening | 19 | $24 |
| BODY MASS INDEX DOCD | 287 | $0 |
Drugs they prescribed that Part D paid
$49,601
Pharmacies billed $49,601 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
508 generic and fewer than 11 brand-name prescriptions · $49,601 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Atorvastatin | 59 | $470 | $8 |
| Levothyroxine | 38 | $408 | $11 |
| Diclofenac | 11 | $239 | $22 |
| Metformin | 28 | $180 | $6 |
| Losartan | 28 | $154 | $6 |
See all 14 drugs
| Atorvastatin | 59 | $470 | $8 |
| Levothyroxine | 38 | $408 | $11 |
| Diclofenac | 11 | $239 | $22 |
| Metformin | 28 | $180 | $6 |
| Losartan | 28 | $154 | $6 |
| Metoprolol | 13 | $150 | $12 |
| Amlodipine Besylate | 39 | $129 | $3 |
| Lisinopril | 18 | $121 | $7 |
| Gabapentin | 14 | $109 | $8 |
| Alendronate | 11 | $94 | $9 |
| Hydrochlorothiazide | 27 | $75 | $3 |
| Fluticasone Propionate | 13 | $74 | $6 |
| Rosuvastatin | 12 | $72 | $6 |
| Omeprazole | 14 | $72 | $5 |
Year by year
| 2024 | 592 | 124 | None | None | $49,601 |
| 2023 | 501 | 54 | 0% (0) | None | $47,390 |
| 2022 | 257 | 45 | None | 10% | $28,512 |
| 2021 | 191 | 33 | 0% (0) | None | $17,020 |
| 2020 | 127 | 27 | 0% (0) | None | $10,805 |
| 2019 | 11 | None | 0% (0) | None | $1,567 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Levothyroxine | 38 | $935 | $25 |
| Losartan | 31 | $812 | $26 |
| Rosuvastatin | 11 | $613 | $56 |
| Atorvastatin | 34 | $603 | $18 |
| Amlodipine Besylate | 34 | $436 | $13 |
| Metformin | 43 | $430 | $10 |
| Pravastatin | 14 | $318 | $23 |
| Metoprolol | 14 | $265 | $19 |
| Lisinopril | 25 | $199 | $8 |
| Alendronate | 11 | $165 | $15 |
| Fluticasone Propionate | 16 | $152 | $10 |
| Furosemide | 12 | $117 | $10 |
| Hydrochlorothiazide | 14 | $63 | $4 |
2022: 5 drugs
| Losartan | 15 | $323 | $22 |
| Levothyroxine | 13 | $239 | $18 |
| Metformin | 25 | $233 | $9 |
| Atorvastatin | 21 | $181 | $9 |
| Amlodipine Besylate | 18 | $163 | $9 |
2021: 5 drugs
| Atorvastatin | 26 | $483 | $19 |
| Levothyroxine | 11 | $244 | $22 |
| Gabapentin | 14 | $129 | $9 |
| Amlodipine Besylate | 16 | $117 | $7 |
| Metformin | 13 | $111 | $9 |
2020: 4 drugs
| Levothyroxine | 11 | $307 | $28 |
| Lisinopril | 15 | $115 | $8 |
| Gabapentin | 12 | $92 | $8 |
| Metformin | 12 | $79 | $7 |
Professional record
- NPI
- 1902300957
- Licence
- CA A163608California A163608: Current · expires 2027-07-31
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 900 Miramonte Ave, Mountain View, CA, 94040
- NPI first listed
- 2018-03-22
- NPI last updated
- 2023-02-24
- NPI record certified
- 2023-02-24
This is when the NPI record was last certified, not a medical board exam.